Savara Q2 loss widens as operating expenses rise
Savara Q2 loss widens as operating expenses rise
Overview
US rare respiratory drug developer's Q2 net loss widened from prior year
Operating expenses rose, driven by higher personnel costs and commercial launch preparations
Company ended Q2 with $173 mln in cash and short-term investments
Outlook
Savara expects FDA decision on MOLBREEVI by Nov. 22, 2026
Company anticipates EMA and MHRA regulatory decisions in Q1 2027 and Q4 2026
Savara says focus is on potential U.S. launch of MOLBREEVI, supported by current cash position
Result Drivers
PERSONNEL COSTS - Co said higher personnel costs, mainly from increased stock-based compensation and headcount, drove up R&D and G&A expenses
COMMERCIAL PREPARATIONS - Co cited higher spending on commercial activities and infrastructure to support planned MOLBREEVI launch
Company press release: ID:nBwL1xRga
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Loss Per Share |
| $0.16 |
|
Q2 Net Loss |
| $40.23 mln |
|
Q2 Income from Operations |
| -$40.97 mln |
|
Q2 Operating Expenses |
| $40.97 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Savara Inc. is $10.25, about 78.9% above its August 10 closing price of $5.73
Reuters Recommended Reads
Aug 11 - Protara Therapeutics Q2 net loss widens on higher expenses
Aug 11 - Neurogene Q2 adjusted loss per share misses estimates on employee costs
Aug 10 - Bristol Myers to build $2.3 billion manufacturing site in Houston
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)